Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    July 2022
  1. OAKNIN A, Monk BJ, Vergote I, Cristina de Melo A, et al
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer. 2022 Jul 31. pii: S0959-8049(22)00160.
    PubMed     Abstract available


  2. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available


  3. PASHANKAR F, Hanley K, Lockley M, Stoneham S, et al
    Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
    Eur J Cancer. 2022;173:59-70.
    PubMed     Abstract available


    June 2022
  4. PESENTI C, Beltrame L, Velle A, Fruscio R, et al
    Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
    Eur J Cancer. 2022;171:85-95.
    PubMed     Abstract available


  5. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    PubMed    


  6. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available


    May 2022
  7. SIMON S, Francis KE, Dalrymple JE, Gebski V, et al
    Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2022;170:169-178.
    PubMed     Abstract available


  8. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available


  9. PAULET L, Trecourt A, Leary A, Peron J, et al
    Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Eur J Cancer. 2022;166:87-99.
    PubMed     Abstract available


    April 2022
  10. AKESSON A, Adok C, Dahm-Kahler P
    Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
    Eur J Cancer. 2022;169:54-63.
    PubMed     Abstract available


  11. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available


    March 2022
  12. CARTER TJ, George C, Harwood C, Nathan P, et al
    Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.
    Eur J Cancer. 2022;166:240-253.
    PubMed     Abstract available


    December 2021
  13. DITTO A, De Cecco L, Paolini B, Alberti P, et al
    Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Eur J Cancer. 2021;161:55-63.
    PubMed     Abstract available


  14. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    PubMed     Abstract available


    October 2021
  15. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Eur J Cancer. 2021;158:111-122.
    PubMed     Abstract available


    September 2021
  16. VERGOTE I, Ray-Coquard I, Anderson DM, Cantuaria G, et al
    Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Eur J Cancer. 2021;157:415-423.
    PubMed     Abstract available


  17. MATSUO K, Klar M, Mohrbacher AF, Roman LD, et al
    Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
    Eur J Cancer. 2021;157:59-62.
    PubMed    


  18. KANTIDAKIS G, Litiere S, Neven A, Vinches M, et al
    Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sar
    Eur J Cancer. 2021;154:253-268.
    PubMed     Abstract available


  19. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    PubMed     Abstract available


    August 2021
  20. KAHAN Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, et al
    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Eur J Cancer. 2021;156:70-82.
    PubMed     Abstract available


  21. JOHANSSON ALV, Fredriksson I, Mellemkjaer L, Stensheim H, et al
    Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018.
    Eur J Cancer. 2021;155:106-115.
    PubMed     Abstract available


    July 2021
  22. TJOKROWIDJAJA A, Friedlander M, Lord SJ, Asher R, et al
    Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
    Eur J Cancer. 2021;154:190-200.
    PubMed     Abstract available


    June 2021
  23. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed     Abstract available


  24. BERGAMINI A, Sarwar N, Ferrandina G, Scarfone G, et al
    Response to the Letter to the Editor by Lockley et al. commenting on 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis'.
    Eur J Cancer. 2021 Jun 7. pii: S0959-8049(21)00284.
    PubMed    


  25. LOCKLEY M, Stoneham S, Shamash J, Pashankar F, et al
    Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis'.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00283.
    PubMed    


    May 2021
  26. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    PubMed     Abstract available


  27. WENZEL HHB, Bekkers RLM, Lemmens VEPP, Van der Aa MA, et al
    No improvement in survival of older women with cervical cancer-A nationwide study.
    Eur J Cancer. 2021;151:159-167.
    PubMed     Abstract available


    April 2021
  28. SOUKUPOVA J, Zemankova P, Nehasil P, Kleibl Z, et al
    Letter to the Editor: Comments on ERCC3 as a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 21. pii: S0959-8049(21)00181.
    PubMed    


  29. STRADELLA A, Del Valle J, Brunet J, Lazaro C, et al
    Response to letter re: ERCC3 a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 19. pii: S0959-8049(21)00182.
    PubMed    


    March 2021
  30. MATHEVET P, Lecuru F, Uzan C, Boutitie F, et al
    Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).
    Eur J Cancer. 2021;148:307-315.
    PubMed     Abstract available


  31. FRANCIS KE, Gebski V, Lord SJ, Friedlander M, et al
    Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event repor
    Eur J Cancer. 2021;148:251-259.
    PubMed     Abstract available


  32. SEPPALA TT, Dominguez-Valentin M, Crosbie EJ, Engel C, et al
    Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    Eur J Cancer. 2021;148:124-133.
    PubMed     Abstract available


  33. MATSUO K, Shimada M, Matsuzaki S, Enomoto T, et al
    Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic.
    Eur J Cancer. 2021;148:117-120.
    PubMed    


  34. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    PubMed    


  35. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available


    February 2021
  36. ANDERSON RA, Clatot F, Demeestere I, Lambertini M, et al
    Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments.
    Eur J Cancer. 2021;144:310-316.
    PubMed     Abstract available


    January 2021
  37. FALCONER H, Yin L, Salehi S, Altman D, et al
    Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.
    Eur J Cancer. 2021;145:38-43.
    PubMed     Abstract available


  38. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    PubMed     Abstract available


    December 2020
  39. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    PubMed     Abstract available


  40. FERRANDINA G, Aristei C, Biondetti PR, Cananzi FCM, et al
    Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168].
    Eur J Cancer. 2020 Dec 19. pii: S0959-8049(20)31301.
    PubMed    


  41. DITTO A, Casarin J, Pinelli C, Perrone AM, et al
    Corrigendum to "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group" [European Journa
    Eur J Cancer. 2020 Dec 17. pii: S0959-8049(20)31355.
    PubMed    


  42. CIBULA D, Dostalek L, Hillemanns P, Scambia G, et al
    Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.
    Eur J Cancer. 2020;143:88-100.
    PubMed     Abstract available


    November 2020
  43. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    PubMed     Abstract available


  44. RESTAINO S, Tortorella L, Dinoi G, Zannoni GF, et al
    Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.
    Eur J Cancer. 2020;142:29-37.
    PubMed     Abstract available


  45. KANG S, Yu YL, Cho SY, Park SY, et al
    Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
    Eur J Cancer. 2020;141:185-192.
    PubMed     Abstract available


  46. MATSUO K, Wright JD, Matsuzaki S, Roman LD, et al
    Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence.
    Eur J Cancer. 2020;140:149-150.
    PubMed    


    October 2020
  47. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed     Abstract available


  48. DITTO A, Casarin I, Perrone AM, Scollo P, et al
    Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group.
    Eur J Cancer. 2020;140:1-10.
    PubMed     Abstract available


    September 2020
  49. MATSUO K, Huang Y, Matsuzaki S, Klar M, et al
    Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic.
    Eur J Cancer. 2020;139:173-176.
    PubMed    


  50. FERRANDINA G, Cynthia A, Raimondo BP, Maria CFC, et al
    Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
    Eur J Cancer. 2020;139:149-168.
    PubMed     Abstract available


  51. BISCH S, Nelson G
    Randomised controlled trial confirms benefit of enhanced recovery after surgery on length of stay in ovarian cancer: How low can we go?
    Eur J Cancer. 2020;139:90-91.
    PubMed    


  52. TJOKROWIDJAJA A, Lee CK, Friedlander M, Gebski V, et al
    Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    Eur J Cancer. 2020;139:59-67.
    PubMed     Abstract available


    March 2020
  53. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: